Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. More Details
Excellent balance sheet with proven track record.
Share Price & News
How has Hunan Er-Kang Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 300267 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 300267's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 300267 underperformed the CN Pharmaceuticals industry which returned -9% over the past year.
Return vs Market: 300267 underperformed the CN Market which returned 9.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Hunan Er-Kang Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hunan Er-Kang Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 300267 (CN¥3.82) is trading below our estimate of fair value (CN¥5.35)
Significantly Below Fair Value: 300267 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 300267 is poor value based on its PE Ratio (33.8x) compared to the CN Pharmaceuticals industry average (29.5x).
PE vs Market: 300267 is poor value based on its PE Ratio (33.8x) compared to the CN market (31.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 300267's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 300267 is good value based on its PB Ratio (1.3x) compared to the CN Pharmaceuticals industry average (2.7x).
How is Hunan Er-Kang Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hunan Er-Kang Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Hunan Er-Kang Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300267 has high quality earnings.
Growing Profit Margin: 300267's current net profit margins (10%) are higher than last year (3.9%).
Past Earnings Growth Analysis
Earnings Trend: 300267's earnings have declined by 41.2% per year over the past 5 years.
Accelerating Growth: 300267's earnings growth over the past year (146%) exceeds its 5-year average (-41.2% per year).
Earnings vs Industry: 300267 earnings growth over the past year (146%) exceeded the Pharmaceuticals industry 25%.
Return on Equity
High ROE: 300267's Return on Equity (3.9%) is considered low.
How is Hunan Er-Kang Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 300267's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥890.4M).
Long Term Liabilities: 300267's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥60.1M).
Debt to Equity History and Analysis
Debt Level: 300267's debt to equity ratio (11.3%) is considered satisfactory.
Reducing Debt: 300267's debt to equity ratio has increased from 4.3% to 11.3% over the past 5 years.
Debt Coverage: 300267's debt is well covered by operating cash flow (60.7%).
Interest Coverage: 300267 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Hunan Er-Kang Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 300267's dividend (1.31%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).
High Dividend: 300267's dividend (1.31%) is low compared to the top 25% of dividend payers in the CN market (1.87%).
Stability and Growth of Payments
Stable Dividend: 300267 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 300267's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.2%), 300267's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fangwen Shuai (54 yo)
Mr. Fangwen Shuai serves as the Chairman, Chief executive Officer and Secretary of Hunan Er-Kang Pharmaceutical Co., Ltd.
Experienced Management: 300267's management team is seasoned and experienced (8.7 years average tenure).
Experienced Board: 300267's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hunan Er-Kang Pharmaceutical Co., Ltd's company bio, employee growth, exchange listings and data sources
- Name: Hunan Er-Kang Pharmaceutical Co., Ltd
- Ticker: 300267
- Exchange: SZSE
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥7.879b
- Shares outstanding: 2.06b
- Website: https://www.hnerkang.com
Number of Employees
- Hunan Er-Kang Pharmaceutical Co., Ltd
- Liuyang National Economic & Technical Development Zone
- Hunan Province
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, d...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/27 16:37|
|End of Day Share Price||2021/07/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.